Brief: Hanall Biopharma Reports Q3 2024 Financial Results And Provides Business Update
01/11/2024 12:19
Nov 1 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA REPORTS Q3 2024 FINANCIAL RESULTS AND
PROVIDES
BUSINESS UPDATE
* HANALL BIOPHARMA CO LTD: Q3 TOTAL REVENUE OF 36.8 BILLION
KRW
Source text: ID:nPnb8WFDXa
Further company coverage: 009420.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies